Clinical trials: Survival Outcomes
Breast Cancer, Malignant Neoplasm of Breast
A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer
Palbociclib, the first oral CDK4/6 inhibitor, is an approved medicine indicated for the treatment of a kind of advanced/metastatic breast cancer (MBC), called hormone receptors positive (HR+)/ Human epidermal growth factor…
- Trial name
- NCT06495164
- Testing
- Palbociclib, Aromatase inhibitor, Ribociclib
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Pfizer
Metastatic Non-small Cell Lung Cancer, Neoplasm
Body Composition and Inflammatory-Metabolic Indices in Immunotherapy-Treated Metastatic Non-Small Cell Lung Cancer: The SARC-CTI Study
This retrospective, single-center observational cohort study evaluates inflammatory-metabolic, cachexia-related, and computed tomography (CT)-derived body-composition markers in patients with metastatic non-small cell lung cancer…
- Trial name
- SARC-CTI (NCT07192926)
- Testing
- Immune Checkpoint Inhibitor-Based Therapy
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 155 people
- Sponsor
- Ankara Etlik City Hospital
Ovarian Carcinoma, Platinum-resistant Ovarian Cancer
Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer
This study is a prospective, multicenter, phase II clinical trial to evaluate the efficacy and safety of albumin-bound paclitaxel combined with bevacizumab for platinum-resistant recurrent epithelial ovarian cancer.
- Conditions
- Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Recurrent Ovarian Carcinoma, Albumin-bound Paclitaxel
- Trial name
- NCT05310344
- Testing
- Albumin-bound paclitaxel and bevacizumab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Lei Li
Gynaecological Oncology
Survival Outcomes of Gynecologic Oncology Patients at Assiut University
This retrospective cohort study investigates survival outcomes of gynecological oncology patients treated at Assiut University Hospital between 2022 and 2025, comparing them to international benchmarks and assessing factors…
- Trial name
- NCT07232212
- Volunteers
- 200 people
- Sponsor
- Assiut University
Kidney Transplant Failure and Rejection
Anti-Angiotensin II Type 1 Receptor Antibodies and Kidney Transplant Outcomes
Incompatibility between non-genetically identical donors and recipients has been increasingly recognized as the main contributing factor to solid allograft rejection and failure, through the triggering of donor-specific responses…
- Trial name
- NCT03466775
- Testing
- Anti-angiotensin II type 1 receptor antibody measurement, Measurement of ENDAT expression level allograft, Allograft survival
- Where
- 2 sites in France
- Volunteers
- 1,845 people
- Sponsor
- Paris Translational Research Center for Organ Transplantation
Glioma
Tessa Jowell BRAIN MATRIX - Platform Study
The main aim of the Tessa Jowell BRAIN MATRIX - Platform Study is to more precisely determine the exact type of tumour patients have by developing the essential infrastructure to provide rapid and accurate molecular diagnosis.
- Trial name
- BRAIN MATRIX (NCT04274283)
- Testing
- Matched Tumour and Blood Sample - Research Pathway, Matched Tumour and Blood Sample - NHS GMS pathway
- Where
- 14 sites in United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- University of Birmingham
Lymphoma, Malignant Solid Neoplasm
Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial
This phase III trial compares the effect of geriatric evaluation and management with survivorship health education (GEM-S) to usual care on patient-reported physical function in older survivors of cancer.
- Trial name
- GEM-S (NCT05006482)
- Testing
- Best Practice, Comprehensive Geriatric Assessment, Educational Intervention
- Where
- 45 sites in United States
- Volunteers
- 668 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Ovarian Cancer, Breast Cancer
Comprehensive Outcomes for After Cancer Health
This study intends to explore feasibility, acceptability, and outcomes related to the use of a digital health coaching intervention for individuals who have completed primary therapy for cancer.
- Conditions
- Ovarian Cancer, Breast Cancer, Lung Cancer, Gastric Cancer
- Trial name
- COACH (NCT05349227)
- Testing
- Digital Health Coaching Program, Fitbit
- Where
- 7 sites in United States
- Volunteers
- 625 people, healthy volunteers welcome
- Sponsor
- Pack Health
Kidney Transplant Failure
HLA Eplet Mismatches to Predict Long-term Kidney Transplant Outcomes
Human leukocyte antigen (HLA) matching evaluates the degree of compatibility between donors and organ transplant recipients and assesses broad antigen differences that may influence immune responses post-transplant.
- Trial name
- NCT07269275
- Testing
- No intervention
- Where
- France
- Volunteers
- 5,525 people
- Sponsor
- Paris Translational Research Center for Organ Transplantation
High-Grade Osteosarcoma
Treatment Patterns and Survival Outcomes in High-Grade Osteosarcoma: A Multicenter Retrospective Study
This is a multicenter, medical-record-based, retrospective observational study of approximately 400 patients with high-grade osteosarcoma treated at four sites in the Republic of Korea.
- Trial name
- NCT07878364
- Where
- 4 sites in South Korea
- Volunteers
- 400 people
- Sponsor
- MedPacto, Inc.
Melanoma, Surgery
Trial of Surgical Excision Margins in Thick Primary Melanoma
Objectives: The purpose of this study was to assess the effects of an excision margin of 2 cm versus 4 cm for patients with primary cutaneous malignant melanoma (CMM).
- Conditions
- Melanoma, Surgery, Treatment Outcome
- Trial name
- NCT01183936
- Testing
- 2-cm margin, 4-cm margin
- Volunteers
- 936 people
- Sponsor
- Karolinska Institutet
Lymphoma, Non-Hodgkin
Evaluation of Lymphoma Prognosis and Survivorship in Recently Diagnosed Patients, LEO Study
The goal of this infrastructure protocol is to build and maintain a large and diverse observational cohort study to support broad and cutting-edge research focused on NHL prognosis and survivorship.
- Trial name
- LEO (NCT04996706)
- Where
- 12 sites in United States
- Volunteers
- 21,000 people
- Sponsor
- Mayo Clinic
Breast Cancer, Breast Cancer Survivorship
Patient-Initiated Follow-Up for Women After Early Breast Cancer Treatment (LYSA2PIFU)
Women treated for early-stage breast cancer commonly experience ongoing treatment-related symptoms while receiving adjuvant endocrine therapy.
- Conditions
- Breast Cancer, Breast Cancer Survivorship, Cancer Survivorship, Endocrine Therapy
- Trial name
- LYSA2PIFU (NCT07840534)
- Testing
- Patient-Initiated Follow-Up and ePRO Symptom Management
- Where
- Ireland
- Volunteers
- 30 people
- Sponsor
- University College Cork
Muscle-Invasive Bladder Carcinoma, Chemotherapy Effect
Role of NAC in cT0 Muscle-invasive Bladder Cancer After Maximal TURBt
This prospective randomized controlled trial (RCT) is designed to provide high level evidence describing the non-inferiority of radical cystectomy (RC) alone versus neoadjuvant chemotherapy (NAC) plus RC on survival outcomes of…
- Conditions
- Muscle-Invasive Bladder Carcinoma, Chemotherapy Effect, Surgery
- Trial name
- NCT05776758
- Testing
- cisplatin based neoadjuvant chemotherapy, Radical cystectomy alone
- Where
- Italy
- Volunteers
- 236 people
- Sponsor
- Regina Elena Cancer Institute
Urothelial Carcinoma of the Bladder, Muscle Invasive Bladder Cancer (MIBC)
Perioperative Systemic Therapies in Muscle-Invasive Bladder Cancer (GUARDIANS)
This is a multicenter, non-interventional, prospective and retrospective observational patient registry study of adults with muscle-invasive bladder cancer receiving perioperative systemic therapy as part of routine clinical…
- Trial name
- GUARDIANS (NCT07855926)
- Testing
- Perioperative Systemic Therapy Registry
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- LMU Klinikum
Advanced Cancer
Outcomes of Triaged Family Care in Advanced Cancer
The purpose of this study is to assess the quality of life of patients with advanced cancer and their family caregivers and to evaluate two doses of a family-based program of care versus control.
- Trial name
- FOCUS-Triage (NCT00709176)
- Testing
- Brief FOCUS Program, Extensive FOCUS Program
- Where
- 5 sites in United States
- Volunteers
- 484 people
- Sponsor
- University of Michigan
Cancer
Patient-reported Outcomes-driven Supportive Care Navigation Among Hispanic/Latinx Cancer Patients
This is a randomized controlled, type 1 hybrid effectiveness-implementation trial to evaluate the effectiveness of a patient-reported outcomes (PRO)-driven culturally grounded supportive care navigation in reducing healthcare…
- Trial name
- NCT07787806
- Testing
- Patient-Reported Outcomes (PRO)-driven supportive care navigation
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- University of California, Irvine
Non Small Cell Lung Cancer
Influence of the Use of the Diabetic Drug Metformin on the Overall Survival and Treatment-related Toxicity in Advanced Stage Non-small Cell Lung Cancer Patients.
There are preliminary data suggesting that patients suffering from non-insulin-dependent diabetes mellitus, treated with metformin, have improved local tumor control.
- Trial name
- Metformin (NCT02109549)
- Where
- 3 sites in Netherlands
- Volunteers
- 70 people
- Sponsor
- Maastricht Radiation Oncology
Osteoarthritis of Hip, Traumatic Arthritis of Hip
Long-Term Multi-center Evaluation of E-Poly and Regenerex
There are two distinct aims of this study: 1. This prospective study is designed to document the long-term (10-year) radiographic and clinical outcomes of a new type of highly cross-linked polyethylene liner which contains…
- Trial name
- NCT00545285
- Testing
- Total Hip Arthroplasty
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Massachusetts General Hospital
Acute Abdomen
Upper Gastrointestinal Perforations: a Nationwide Registry-based Study
The primary aim of this project is to increase the knowledge about how perforations in the esophagus, stomach and small intestine are treated on a national level.
- Trial name
- NCT06154603
- Testing
- Surgical treatment type
- Where
- Sweden
- Volunteers
- 2,000 people
- Sponsor
- Region Stockholm